Press coverage about AMAG Pharmaceuticals (NASDAQ:AMAG) has been trending neutral recently, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. AMAG Pharmaceuticals earned a news sentiment score of 0.50 on their scale. InfoTrie also assigned headlines about the specialty pharmaceutical company an news buzz score of 10 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company’s share price in the near term.
AMAG traded up $0.35 on Thursday, reaching $9.00. The stock had a trading volume of 2,456,100 shares, compared to its average volume of 783,608. AMAG Pharmaceuticals has a 12-month low of $7.81 and a 12-month high of $26.10. The company has a current ratio of 2.30, a quick ratio of 2.13 and a debt-to-equity ratio of 0.44. The company has a 50-day moving average price of $9.46. The company has a market cap of $288.35 million, a P/E ratio of -2.32 and a beta of 0.47.
AMAG Pharmaceuticals (NASDAQ:AMAG) last released its earnings results on Tuesday, May 7th. The specialty pharmaceutical company reported ($3.32) EPS for the quarter, missing analysts’ consensus estimates of ($0.55) by ($2.77). AMAG Pharmaceuticals had a negative return on equity of 26.33% and a negative net margin of 30.90%. The company had revenue of $75.80 million for the quarter, compared to analysts’ expectations of $90.13 million. During the same period in the prior year, the firm earned ($1.59) EPS. The firm’s revenue for the quarter was down 35.4% on a year-over-year basis. Analysts predict that AMAG Pharmaceuticals will post -2.15 EPS for the current year.
In related news, insider Elizabeth Scott Bolgiano bought 5,000 shares of the stock in a transaction dated Thursday, May 9th. The stock was acquired at an average price of $10.93 per share, for a total transaction of $54,650.00. Following the acquisition, the insider now owns 74,847 shares in the company, valued at approximately $818,077.71. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, major shareholder Armistice Capital, Llc bought 44,000 shares of the stock in a transaction dated Thursday, June 27th. The stock was bought at an average price of $9.52 per share, with a total value of $418,880.00. The disclosure for this purchase can be found here. Over the last three months, insiders acquired 328,016 shares of company stock worth $2,904,577. Insiders own 4.90% of the company’s stock.
AMAG Pharmaceuticals Company Profile
AMAG Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and commercializes therapeutics for maternal and women's health, anemia management, and cancer supportive care in the United States. It markets Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds.
Further Reading: What are municipal bonds?
Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.